0 149

Cited 12 times in

A prospective randomized trails comparing intravenous 5 fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer

 Jin Sik Min  ;  Nam Kyu Kim  ;  Jea Kun Park  ;  Seong Hyun Yun  ;  Jae Kyung Noh 
 Annals of Surgical Oncology, Vol.7(9) : 674-679, 2000 
Journal Title
Issue Date
Adenocarcinoma/drug therapy* ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Administration, Oral ; Antimetabolites, Antineoplastic/administration & dosage* ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Floxuridine/administration & dosage* ; Fluorouracil/administration & dosage* ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Postoperative Period ; Prospective Studies ; Quality of Life ; Rectal Neoplasms/drug therapy* ; Rectal Neoplasms/mortality ; Rectal Neoplasms/pathology ; Rectal Neoplasms/surgery ; Treatment Outcome
Rectal cancer ; Postoperative adjuvant ; 5-Fluorouracil ; Doxifluridine
Background: Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate. Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy, but oral 5-FU derivatives have been shown a comparable antitumor activity. Intravenous 5-FU and oral doxifluridine were compared with respect to therapeutic efficacy, drug toxicity, and quality of life.
Methods: A total of 166 patients were randomized to receive intravenous 5-FU (450mg/m2/day) or oral doxifluridine (900mg/m2/day) in combination with leucovorin (20mg/m2/day) for depth of invasion, nodal status, metastasis (TNM) stage II and III patients between October 1997 and February 1999. Consecutive daily intravenous infusion for 5 days per every month for a total of 12 cycles (IV arm, n 5 74) and oral doxifluridine daily for 3 weeks and 1 week rest for a total of 12 cycles (oral arm, n 5 92). Drug toxicity and quality of life were observed. Quality of life was scored according to 22 daily activity items (good, $ 71; fair, , 70; poor, , 52).
Results: There was no difference of sex between two groups (IV arm: male/female 5 45/29, oral arm: male/female 5 59/33). The mean age was 52.3 vs. 59.5, respectively. There was also no difference of TNM stage distribution and type of operation between groups (P . .05). Mean numbers of chemotherapy cycles were 6.5 6 3.7 (IV arm) vs. 7.2 6 4.3 (oral arm), respectively. The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5%) in the oral arm, respectively (P 5 .937). Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II;1.1%) in the oral
arm, respectively. Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively. The most common site of systemic recurrence was the liver. Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm. Diarrhea was more common in the oral arm. Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy. Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P , .05).
Conclusions: Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy. The oral regimen also can be safely given with appropriate toxicity and tolerability.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Nam Kyu(김남규) ORCID logo https://orcid.org/0000-0003-0639-5632
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.